Reinhard Dummer

Reinhard Dummer is one of Europe's foremost melanoma specialists who has co-led pivotal adjuvant trials including COMBI-AD evaluating dabrafenib plus trametinib in BRAF V600-mutated resected stage III melanoma. His research established combination BRAF/MEK inhibition as a standard adjuvant option for patients with BRAF-mutated high-risk resected melanoma, providing a targeted alternative to checkpoint immunotherapy. He has extensively investigated mechanisms of acquired resistance to BRAF/MEK-targeted therapy in the metastatic and adjuvant settings and strategies to re-sensitize tumors upon relapse. His clinical contributions span both targeted therapy and immunotherapy approaches for melanoma across disease stages.